Reporting of adverse events ONLY

Patients should always seek the advice of a doctor or pharmacist in case of adverse events.

If you wish to report an adverse event to ELC Group s.r.o., please find the contact information below:

+420 224 910 672

(from 09.00-17.30 CET)

+420 226 251 459

(non-stop 24/7)

To contact us about any other issue please call:

+420 22 491 0000or our regional offices.

Hlášení nežádoucích príhod

Pacienti by meli vždy požádat o radu svého lékare nebo lékárníka v prípade výskytu nežádoucích príhod.

Pokud chcete nahlásit nežádoucí príhodu spolecnosti ELC Group s r.o., prosím využijte kontaktních údaju níže:

+420 224 910 672

(09.00-17.30 CET)

+420 226 251 459

(non-stop 24/7)

Pro záležitosti, které se netýkaji farmakovigilance, kontaktujte prosím recepci:

+420 22 491 0000 nebo naše další pobočky.

China Pharma and Biotech’s European Market Access and BD Partnership Opportunities

Date: 24.11.2021

Time: 13:00 CET

Price: Free of charge

On Thursday 24th November /  European time at 13:00 CET / Beijing Time 20:00, PLG will be hosting a seminar providing an overview of China Pharma and Biotech’s European Market Access and BD Partnership Opportunities.

The organizers are:

*Shanghai Sinoexpo Informa Markets International Exhibition Co., Ltd.

*Hangzhou Angine Biotech Co., Ltd.

*Product Life Group (PLG)

Supporting Organization:

* International Affairs Committee of China Pharmaceutical Enterprise Association (CPEA)

* “Pharma Going Global” Alliance

We are going to take you through the following topics:


  • 13:00-13:10 China Pharmaceutical Internationalization Status from a Global BD perspective

By: Leo Luo:  Director of International Affairs of China Pharmaceutical Enterprise Association (CPEA),  and Managing Director of Hangzhou Angine Biotech

  • 13:10-13:30 Why Chinese biotech & Pharma companies should expend their business in Europe

By:Dr Ahmed Bouzidi, VP Biotech ;

  • 13:30-13:50 EU Clinical strategy – How to map an optimal pathway in your product’s clinical development

By: Dr Amit Salvi ;

  • 13:50-14:10 Triggering GMP Inspection from European Authorities for Finished Dosage Facility & Impact of COVID – 19:

By: Dr Chetan Javia ;

  • 14:10-14:30 Registration, Pricing & Reimbursement models in Europe

By: Prof. Jean-Jacques Zambrowski   MD – Strategy & Market Access Advisor.

  • 14:30-14:50 Pharmacovigilance requirements in US and EU

By: Dr Ioana Maria Busita ;

  • 14:50-15:10 Seminar Conclusion as well as Opportunities & Challenges Post-COVID :

By: Dr Ahmed Bouzidi, VP Biotech ; Mr. Leo Luo, Managing Director of Angine Biotech

  • 15:10-15:30 Q&A

To participate, please fill in the form below. You will then receive an invitation to this seminar. Please note that the number of participants is limited.